RGBP Research | Milton Maxwell

RGBP

Regen BioPharma, Inc.

0.0084

-0.0016-16%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

463.97K

P/E (TTM)

Basic EPS (TTM)

-0.01

Dividend Yield

Recent Filings

8-K

Stock dividend declared

1/21/26Jan 21, 2026

Regen Biopharma's board declared a stock dividend on January 19, 2026, issuing one share of authorized but unissued Series A Preferred Stock per common, Series A, AA, M, or NC share held as of the February 3 record date, payable around February 9. This one-for-one distribution dilutes common equity while boosting preferred holdings. No cash impact disclosed.

10-K

FY2025 results

12/30/25Dec 30, 2025

Regen Biopharma posted FY2025 net revenue of $236,561 from licensing deals with Zander Therapeutics and Oncology Pharma, flat year-over-year, while trimming operating loss to $338,540 from $417,221 via slashed R&D spend. Yet net loss ballooned to $1.3 million, hammered by $676K derivative expense and $158K interest. No quarterly breakdowns disclosed in the 10-K. Cash ticked up to $69,555 on $452K financing inflows, but $6.2M working capital deficit signals distress. No clinical trials advanced. Dependence on key personnel threatens momentum.

8-K

Issued 23.7M shares, raised $192K

11/13/25Nov 13, 2025

Regen Biopharma issued 23,680,000 common shares in October-November 2025, raising $191,800 via Tier 2 Regulation A offerings and settling $43,740 in convertible debt plus interest. Sales handled directly by management, no underwriters. Capital influx bolsters cash position.

8-K

Consulting deals for HemaXellerate trial

10/3/25Oct 3, 2025

Regen Biopharma inked consulting pacts on October 2, 2025, with Dr. Harry Lander and CEO David Koos, each netting 20 million restricted common shares that vest only upon HemaXellerate's Phase I trial success. These deals lock in expertise for the stem cell therapy's safety and efficacy push in drug-refractory aplastic anemia patients, running through October 2028 or trial wrap. Shares dilute the 79.4 million outstanding pool. Forfeiture hits if the consulting ends early.

8-K

Issues 5.8M shares for $58K

9/19/25Sep 19, 2025

Regen Biopharma issued 5,820,000 common shares to unaffiliated investors on September 15-18, 2025, raising $58,200 in cash via Regulation A exemptions, with no commissions paid. Management handled direct sales. Funds bolster working capital. Dilution hits shareholders hard.

About

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also developing HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.

CEO

Dr. David Raymond Koos DBA, Ph.D.

IPO

10/6/2014

Website

https://regenbiopharmainc.com

Employees

Sector

Healthcare

Industry

Biotechnology